Clinical Trial Update: Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating APVO101, a recombinant factor IX product, in previously-treated pediatric patients with Hemophilia B has completed and posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• APVO101 (recombinant factor IX)

Snippet

Sponsor: Medexus Pharma, Inc. | Conditions: Hemophilia B | Phase 3 | Status: COMPLETED | Results posted: 2024-05-16